Xeris Biopharma (XERS) Leerink Global Healthcare Conference 2025 summary

Strategic focus and growth outlook

• Three commercial assets—Recorlev, Gvoke, and Keveyis—are all experiencing strong growth, with over 30% revenue growth guided for the current year and a transformational outlook for 2025.

• Financial discipline and investment prioritization are emphasized, with a commitment to maintaining positive adjusted EBITDA and leveraging cash flow to fuel both commercial and pipeline growth.

• The company is positioned for both short- and long-term shareholder value creation, supported by a robust balance sheet and disciplined expense management.

• Business development remains a focus, but internal assets are prioritized for value creation.

Commercial portfolio performance

• Recorlev benefits from increased clinician awareness and diagnosis of hypercortisolemia, with accelerated growth expected to continue into 2025.

• Gvoke maintains steady growth, targeting the large population of insulin or sulfonylurea users needing rescue medication, with a long runway due to patent protection until 2036.

• Keveyis remains resilient against generic competition, supported by high-touch patient services and proactive patient identification strategies, with steady revenues anticipated.

Pipeline and innovation

• XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism, is phase 3 ready, addressing a significant unmet need for patients with poor oral bioavailability.

• The company is working closely with the FDA on trial design and aims for a mid-year update on phase 3 plans and market opportunity.

• A new CMO with prior company experience has been appointed to strengthen clinical and regulatory strategy, especially for XP-8121 and Recorlev.